Wolters Kluwer lancerer Capego Practice Management – en cloud-løsning til moderne revisions- og bogføringsfirmaer
Dette cloudbaserede softwaresystem samler alt, hvad revisions- og bogføringsfirmaer har brug for, i én kraftfuld, forbundet platform, der er fuldt integreret med Capego-produktserien
Wolters Kluwer Tax & Accounting Danmark er stolte af at kunne annoncere lanceringen af Capego Practice Management, en cloud-baseret løsning designet til at give revisions- og bogføringsfirmaer smartere og mere integrerede arbejdsgange. Capego-pakken samler nu alt, hvad firmaer har brug for – fra kundedata og opgavestyring til fakturering og compliance – i ét sikkert, skalerbart system.
"Capego Practice Management repræsenterer et stort fremskridt i måden, hvorpå revisions- og bogføringsfirmaer kan operere i dagens digitale verden," siger Stefan Wahle, vicepræsident og general manager, Wolters Kluwer Tax & Accounting, Europa Region Nord. "Ved at samle kundesamarbejde, opgavestyring, compliance og fakturering i én fuldt integreret platform hjælper vi firmaer med at arbejde smartere, overholde reglerne og levere enestående service – nu og i fremtiden."
Capego Practice Management bygger på funktionerne i vores globale cloudbaserede regnskabssoftware CCH iFirm, som hjælper med at strømline arbejdsgange, forbedre samarbejdet og øge effektiviteten i driften.
Smartere kundestyring. Bygget til i dag – klar til i morgen.
Capego Practice Management er udviklet til at understøtte det moderne, digitale revisions- og bogføringsfirma. Det giver et omfattende overblik over opgaver, deadlines og ressourcer, så virksomheder kan strømline driften, øge gennemsigtigheden og samarbejde mere effektivt med kunderne.
De vigtigste fordele:
- Cloudbaseret effektivitet: Administrér opgaver, spor tid, fakturér kunder og sikr overholdelse af regler – alt fra én enkelt, intuitiv platform.
- Integrerede moduler: Årsafslutning, skat, e-signering og KYC arbejder problemfrit sammen for at understøtte branchestandardiserede arbejdsgange.
- Skalerbarhed og sikkerhed: Designet til firmaer i alle størrelser med sikker adgang og fremtidssikret infrastruktur.
- Centraliseret kundedatabase: Et samlet overblik over kunder, projekter og ressourcer, der styrker beslutningsprocessen.
Capego Practice Management er designet til at imødekomme de skiftende behov hos nutidens revisions- og bogføringsfirmaer. For nye kunder tilbyder det en moderne, cloudbaseret platform, der samler alt, hvad der er nødvendigt for at levere tjenester af høj kvalitet. For eksisterende kunder, der migrerer fra lokale systemer, bevarer løsningen den velkendte brugervenlighed fra de nuværende værktøjer kombineret med de ekstra fordele, som skalerbarhed, fleksibilitet og problemfri integration giver.
Capego er en cloudbaseret programsuite med produkter, der er designet til at understøtte regnskabs-, revisions- og skattefagfolk. Capego strømliner finansielle arbejdsgange, styrker samarbejdet og hjælper med at sikre overholdelse af lokale regler.
For at få mere at vide om Capego Practice Management, besøg: https://www.wolterskluwer.com/en/solutions/capego-dk/capego-practice-management-dk
Om Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) er en global leder inden for information, softwareløsninger og tjenester til fagfolk inden for sundhedspleje, skat og regnskab, finansiel og virksomhedsmæssig compliance, juridiske og lovgivningsmæssige forhold, virksomhedspræstationer og ESG. Vi hjælper vores kunder med at træffe vigtige beslutninger hver dag ved at levere ekspertløsninger, der kombinerer dyb viden om området med teknologi og tjenester.
Wolters Kluwer rapporterede en årlig omsætning på 5,9 mia. euro i 2024. Koncernen betjener kunder i over 180 lande, har aktiviteter i over 40 lande og beskæftiger ca. 21.600 medarbejdere på verdensplan. Virksomheden har hovedkontor i Alphen aan den Rijn, Holland.
For mere information, besøg www.wolterskluwer.com og følg os på LinkedIn, Facebook, YouTube og Instagram.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20250831114050/da/
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Wolters Kluwer Launches Capego Practice Management - A Cloud Solution for Modern Tax and Accounting Firms1.9.2025 01:00:00 CEST | Press release
This cloud-based software system brings together everything tax and accounting firms need into one powerful, connected platform that’s fully integrated with the Capego suite of products Wolters Kluwer Tax & Accounting Denmark is proud to announce the launch of Capego Practice Management, a cloud-native solution designed to empower tax and accounting firms with smarter, more connected workflows. The Capego suite now brings together everything firms need—from client data and task management to invoicing and compliance—into one secure, scalable system. “Capego Practice Management represents a major leap forward in how tax and accounting firms can operate in today’s digital-first world,” said Stefan Wahle, Vice President & General Manager, Wolters Kluwer Tax & Accounting, Europe Region North. “By bringing together client collaboration, task management, compliance, and invoicing into one fully integrated platform, we’re helping firms work smarter, stay compliant, and deliver exceptional ser
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 11:15:00 CEST | Press release
− Sustained Benefit of Vutrisiran Across Mortality, Cardiovascular Events, Quality of Life and Cardiac Biomarkers Observed Through Up to 48 Months, Including 12 Months from the Ongoing Open-Label Extension, Reinforce Potential as First-Line Treatment for ATTR-CM –− Vutrisiran, which Delivers Rapid Knockdown of Transthyretin, Reduced the Risk of Composite of All-Cause Mortality or First Cardiovascular Event by 37% in the Overall Population and 42% in the Monotherapy Group During the Same Period – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Card
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 08:30:00 CEST | Press release
DEWA will organise the exhibition from 30 September to 2 October 2025 Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial i
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release
Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum